SGLT2 inhibitors – moving on with the evidence - DiabetesontheNet
Orale Begleittherapien bei Typ-1-Diabetes – die Nutzen und Risiken
The Effects of Empagliflozin, an SGLT2 Inhibitor, on Pancreatic β-Cell Mass and Glucose Homeostasis in Type 1 Diabetes | PLOS ONE
FDA weighs risks of new treatment for type 1 diabetes - Diabetes Voice
Cureus | Use of Sodium-Glucose Co-Transporter-2 Inhibitors in Type 1 Diabetics: Are the Benefits Worth the Risks?
Could SGLT2 Inhibitors Be Part of a New Treatment for Type 1 Diabetes? – BETTER
Missouri Society of Health-System Pharmacists - Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors and their role in Type 1 Diabetes
Sodium–glucose cotransporter 2 inhibitor‐associated diabetic ketoacidosis in patients with type 1 diabetes: Metabolic imbalance as an underlying mechanism - Ogawa - 2019 - Journal of Diabetes Investigation - Wiley Online Library
Type 1 diabetes could begin in the womb, new research suggests – Diabetologia
SGLT inhibitors for type 1 diabetes: a finely balanced matter?
Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus | Circulation
Insulin Therapy in Combination With SGLT2 Inhibitors in Type 1 and Type... | Download Table
Efficacy and safety of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: A meta‑analysis of randomized controlled trials
How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes? | Arteriosclerosis, Thrombosis, and Vascular Biology
Lexicon Fires Back after Sanofi Ends Up-to-$1.7B Diabetes Collaboration
The Effects of Empagliflozin, an SGLT2 Inhibitor, on Pancreatic β-Cell Mass and Glucose Homeostasis in Type 1 Diabetes | PLOS ONE
Efficacy and safety of sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct to insulin in young adults with poorly controlled type 1 diabetes (JDRF Study) - Media Centre | EASD
JCM | Free Full-Text | SGLT2 Inhibitors in Type 2 Diabetes Mellitus and Heart Failure—A Concise Review
SGLT-2 Inhibitors in Type 1 Diabetes Mellitus: A Comprehensive Review of the Literature | Bentham Science
FDA says no to Lilly, Boehringer's Jardiance in type 1 diabetes - PMLiVE
News
Type 1 Diabetes and SGLT2 Inhibitors - Children with Diabetes
Summary of evidence for SGLT-2 inhibitors in type 1 diabetes | Download Table
![Sodium-glucose Co-transporter-2 Inhibitors in Type 1 Diabetes—a Dangerous Ally | [current-page:pager]touchENDOCRINOLOGY](https://www.touchendocrinology.com/wp-content/uploads/sites/5/2017/11/table1-minimizing-the-risk-of-diabetic.png "Sodium-glucose Co-transporter-2 Inhibitors in Type 1 Diabetes—a Dangerous Ally | [current-page:pager]touchENDOCRINOLOGY")